Literature DB >> 12113034

Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy.

M Hejna1, C C Zielinski.   

Abstract

Carcinoma of the gallbladder is a rare tumor entity. Apart from surgical intervention, there is no therapeutic measure with curative potential. Therefore, patients with advanced--i.e., unresectable or metastatic-disease present a difficult problem to clinicians, whether to choose a strictly symptomatic treatment or expose the patient to the side effects of potentially ineffective treatment. Despite anecdotal reports about symptomatic palliation and survival advantages, only unrandomized Phase II studies too small to draw meaningful conclusions have been published thus far. Since there is no standard therapy for advanced gallbladder cancer, patients should be offered the opportunity to participate in controlled clinical trials.

Entities:  

Mesh:

Year:  2001        PMID: 12113034     DOI: 10.1586/14737140.1.2.291

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

1.  Evaluation of two modified ECF regimens in the treatment of advanced gallbladder cancer.

Authors:  Jian Dong Wang; Wei Bin Shi; Jun Shen; Peng Yuan Zhuang; Zhi Wei Quan; Xue Feng Wang; Xue Ping Zhou; Song Gang Li; Ying Bin Liu; Yong Yang
Journal:  Med Oncol       Date:  2010-12-07       Impact factor: 3.064

2.  Combination of calcineurin B subunit (CnB) and 5-fluorouracil reverses 5-fluorouracil-induced immunosuppressive effect and enhances the antitumor activity in hepatocellular carcinoma.

Authors:  Wenlong Zhang; Youxiu Zhong; Hongfei Cui; Liya Wang; Rui Yang; Zhenyi Su; Benqiong Xiang; Qun Wei
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

3.  A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.

Authors:  Kazuma Kobayashi; Akihito Tsuji; Sojiro Morita; Tadashi Horimi; Tetsuhiko Shirasaka; Takashi Kanematsu
Journal:  BMC Cancer       Date:  2006-05-06       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.